Monoclonal anti-interleukin-5 treatment suppresses eosinophil but not T-cell functions Source: Eur Respir J 2003; 21: 799-803 Year: 2003
Efficacy and safety of anti-PD-L1 antibody in NSCLC patients who previously treated with anti PD-1 antibodies Source: International Congress 2019 – Treatment of lung cancer Year: 2019
The effects of efalizumab, an anti-CD11a monoclonal antibody (hu1124), on allergen-induced airway inflammation in atopic asthmatic subjects Source: Eur Respir J 2001; 18: Suppl. 33, 350s Year: 2001
Reversing the suppression of T-cells: the role of monoclonal antibodies Source: International Congress 2015 – Stop immune tolerance in lung cancer! Year: 2015
Massive monoclonal expansion of CD4 T-cells specific for a Mycobacterium tuberculosis ESAT-6 peptide Source: Eur Respir J 2012; 40: 152-160 Year: 2012
Study of regulative effect of anti-IL-4 monoclone antibody on Th1/Th2 in the patients of allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 431s Year: 2001
MEMP1972A, an anti-M1 prime monoclonal antibody, reduces serum IgE in healthy and allergic rhinitis subjects Source: Annual Congress 2012 - The best of pharmacology treatment for asthma and COPD Year: 2012
A novel anti-IgE immunotherapeutic, RP01, induces anti-IgE antibodies in human subjects; data from a phase I study Source: Eur Respir J 2007; 30: Suppl. 51, 622s Year: 2007
Impact of age on the efficacy of anti-IL-5 monoclonal antibodies in severe asthmatics Source: International Congress 2019 – Treatment of asthma with monoclonal antibodies Year: 2019
Preclinical development of an IL-13 neutralising antibody, CAT-354, for the treatment of human asthma Source: Eur Respir J 2005; 26: Suppl. 49, 367s Year: 2005
Phase 1 study of a novel, prolonged-action anti-IL-5 monoclonal antibody in asthma Source: Virtual Congress 2021 – Clinical trials in airway diseases: novel treatments and new evidence Year: 2021
Differential cell count in BAL by flow cytometry using CD15 FITC/CD16PE/CD45 PERCP/HLA-DR APC monoclonal antibodies Source: Annual Congress 2011 - Bronchoalveolar lavage and biomarkers in diffuse parenchymal lung disease Year: 2011
A multiple ascending subcutaneous (SC) dose study of MEDI-563, a humanized anti-IL-5Rα monoclonal antibody, in adult asthmatics Source: Annual Congress 2010 - New treatments for asthma and COPD Year: 2010
Treatment with omalizumab (rhuMAb-E25), a monoclonal anti-IgE antibody induces effective changes in subjects with allergic asthma Source: Eur Respir J 2001; 18: Suppl. 33, 37s Year: 2001
Effects of anti-M1 prime monoclonal antibody, MEMP1972A following allergen challenge in patients with mild asthma Source: Annual Congress 2012 - New bronchodilators and other novel drugs for asthma and COPD Year: 2012
TNF-alpha, T-lymphocytes: CD4, CD25, and lymphocytes expressing adhesion molecules: CD11b, CD18, in inflammatory processes of the lower respiratory tract Source: Eur Respir J 2002; 20: Suppl. 38, 274s Year: 2002
Dendritic cells stimulated by agonistic anti-CD40 mAb could elicit activation of lung cancer patients’ autologous cytotoxic T lymphocytes Source: Eur Respir J 2004; 24: Suppl. 48, 673s Year: 2004
Evaluation of bronchial hyperreactivity and other functional parameters in severe asthma patients treated with anti-interleukin-5 monoclonal antibody (IL5) Source: International Congress 2019 – Real-world experience of monoclonal antibodies in asthma Year: 2019
Omalizumab, an anti-immunoglobin E antibody, is not associated with an increased risk of immunological reactions Source: Eur Respir J 2002; 20: Suppl. 38, 108s Year: 2002
sCD30, Bcl-2 and anti-annexin V antibodies - apoptosis associated soluble molecules in atopic subjects Source: Eur Respir J 2002; 20: Suppl. 38, 29s Year: 2002